Recent News

• 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.15.2025 - Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.15.2025 - Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
• 09.15.2025 - Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
• 09.08.2025 - Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.08.2025 - Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
• 09.05.2025 - Spyre Therapeutics Announces Grants of Inducement Awards
• 09.05.2025 - Spyre Therapeutics Announces Grants of Inducement Awards
• 08.05.2025 - Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.05.2025 - Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 09.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2025 - EX-99.1 EX-99.1
• 08.05.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 8-K Current report
• 07.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.16.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors